恒瑞医药(600276.SH)：注射用瑞康曲妥珠单抗药品纳入突破性治疗品种名单

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received breakthrough therapy designation from the National Medical Products Administration for its injectable SHR-A1811, marking the 10th indication for this drug [1] Group 1 - The proposed indication for SHR-A1811 is as a first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2 (ERBB2) activating mutations [1] - SHR-A1811 is expected to be approved for domestic market launch in May 2025, targeting adult patients with unresectable locally advanced or metastatic NSCLC who have previously received at least one systemic therapy [1]